RA0143

antibody from Oursmab
Targeting: CLDN18 SFTPJ
Provider product page for RA0143
Western blot
ELISA
Immunocytochemistry
Flow cytometry
Functional assay

Antibody data

Product number
RA0143 - Provider product page
Provider
Oursmab
Product name
Osemitamab (Biosimilar Reference Antibody) (CLDN18)
Antibody type
Monoclonal
Description
Osemitamab (also known as TST001) is a humanized IgG1-kappa monoclonal antibody that specifically targets claudin-18.2 (CLDN18.2), a tight-junction protein that is normally confined to gastric mucosal epithelial cells but becomes aberrantly exposed and overexpressed in a variety of solid tumors, including gastric, pancreatic, esophageal, and ovarian cancers. As an IgG1 isotype, it is engineered to engage immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). By binding to CLDN18.2, osemitamab aims to induce tumor cell killing through these immune mechanisms and potentially disrupt tumor-specific signaling. It is being developed as a potential therapeutic for CLDN18.2-positive advanced solid tumors, with a focus on gastric/gastroesophageal junction adenocarcinoma.
Reactivity
Human
Isotype
IgG
Vial size
100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
Concentration
Bottled at the concentration indicated on the vial.
Storage
Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
CLDN18 protein structure - RA0143 shown in red.